| Brookhaven Mem Hosp Medical Ctr Hospice 105 West Main St, Patchogue, NY, 11772 | |
| (631) 687-2960 |
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| Name | Brookhaven Mem Hosp Medical Ctr Hospice |
|---|---|
| Location | 105 West Main St, Patchogue, New York |
| Hospice ID | 331537 |
| Category | Part of a hospital |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| SSA county code | 700 |
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| NPI Number | 1609877364 |
| Organization Name | Brookhaven Memorial Hospital Medical Center |
| Address | 105 West Main Street Patchogue, New York, 11772 |
| Phone Number | (631)687-2960 |
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.6 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 97.6 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 85.6 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 96.4 | 97.3 |
| Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 84.5 | 93.3 |
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| Counselors | 0.5 |
| Medical Social Workers | 1.5 |
| Physicians | 1 |
| Registered Nurses | 5.22 |
| Other Personnel | 1.6 |
| Total Employees | 9.82 |
|---|
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| Others | 20 |
| Total Volunteers | 20 |
|---|
News Archive
A biochemical reaction between an enzyme called luciferase and oxygen causes fireflies to glow and is considered one of the most well-known examples of bioluminescence in nature.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago
| Brookhaven Mem Hosp Medical Ctr Hospice Location: 105 West Main St, Patchogue, New York, 11772 Phone: (631) 687-2960 |